Winston Pharmaceuticals, Inc (WPHM) fair value: what the stock is really worth
As of Oct 9, 2026: fair value of Winston Pharmaceuticals, Inc $0.00, price $0.00, upside +0.0%, quality 49 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Winston Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and commercializes therapeutics for pain management.
Show more
Winston Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and commercializes therapeutics for pain management. It focuses on pain indications, such as episodic cluster headache, chronic migraine headache, neuropathic pain syndromes, osteo-and rheumatoid arthritis, and pain and inflammation in inflammatory bowel disease, as well as niche indications. Winston Pharmaceuticals, Inc. was formerly known as Winston Laboratories, Inc. and changed its name to Winston Pharmaceuticals, Inc. in November 2008. The company was incorporated in 1998 and is headquartered in Vernon Hills, Illinois.
Stock analysis
Winston Pharmaceuticals, Inc (WPHM) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 84/100, which puts the data coverage at low.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Winston Pharmaceuticals, Inc reported revenue of $1.4M in FY2009 versus $294K in FY2006, a compound +67.9%/yr. Reported net income was −$2.7M in FY2009.
Key figures
Market cap $7.7K · Net margin −170% · Return on equity −205% · Return on assets (EBIT) −104% · Operating margin −146% · Revenue (TTM) $1.4M · Revenue growth (YoY) −6.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).
What moves the price
The share trades about 67% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −22% fair-value upside, at 0%, WPHM screens cheaper than that median.
Fair Value models
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.33/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+208.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+67.9%
’06
’08
’09
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
Compare Winston Pharmaceuticals, Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 591 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Winston Pharmaceuticals, Inc (WPHM) overvalued or undervalued?
As of Sep 28, 2026, our model estimates a fair value of $0.0001 versus a price of $0.0001, about +0% upside (fairly valued).
What is the fair value of WPHM?
Our model-based fair value for Winston Pharmaceuticals, Inc is $0.0001 (as of Sep 28, 2026), built from audited fundamentals. The current price: $0.0001.
What is the quality score of WPHM?
Winston Pharmaceuticals, Inc has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Winston Pharmaceuticals, Inc (WPHM)?
Our model-based price target is the fair value of $0.0001 (as of Sep 28, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Winston Pharmaceuticals, Inc stock forecast for 2026?
Our models put fair value at $0.0001, about +0% upside versus a price of $0.0001 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of Winston Pharmaceuticals, Inc (WPHM)?
Winston Pharmaceuticals, Inc reported trailing-twelve-month revenue of about $1.4M (latest available figure, as of Sep 28, 2026).
What is the intrinsic value of Winston Pharmaceuticals, Inc (WPHM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Winston Pharmaceuticals, Inc it is $0.0001 per share (as of Sep 28, 2026), against a price of $0.0001. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Winston Pharmaceuticals, Inc stock overvalued or undervalued in 2026?
As of Sep 28, 2026, WPHM trades below its calculated fair value: price $0.0001, fair value $0.0001, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of WPHM?
No. The price is what the market pays today ($0.0001); the fair value is what the company's own numbers justify ($0.0001). For Winston Pharmaceuticals, Inc the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Winston Pharmaceuticals, Inc worth?
The market values Winston Pharmaceuticals, Inc at about $7.7K (market capitalisation, as of Sep 28, 2026). Per share that is $0.0001; our models calculate a fair value of $0.0001 per share.
How solid is the balance sheet of Winston Pharmaceuticals, Inc (WPHM)?
Balance-sheet figures for Winston Pharmaceuticals, Inc (as of Sep 28, 2026): return on equity −204.6%. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is WPHM from its 52-week high?
Winston Pharmaceuticals, Inc trades at $0.0001, about 67% below its 52-week high of $0.0003 and at the low of $0.0001 (as of Oct 9, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0001 is for.
Which stocks are comparable to Winston Pharmaceuticals, Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Winston Pharmaceuticals, Inc stock attractive at the current price?
The data as of Sep 28, 2026: price $0.0001, calculated fair value $0.0001 (+0%), Quality Score 49/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of WPHM calculated?
We run Winston Pharmaceuticals, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0001, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Winston Pharmaceuticals, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Winston Pharmaceuticals, Inc (WPHM)?
The closing price on Oct 9, 2026 was $0.0001. Our model-based fair value is $0.0001, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Winston Pharmaceuticals, Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Winston Pharmaceuticals, Inc
How large is the market capitalisation of Winston Pharmaceuticals, Inc (WPHM)?
The market capitalisation of Winston Pharmaceuticals, Inc is $7.7K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the net margin of Winston Pharmaceuticals, Inc (WPHM)?
The net margin of Winston Pharmaceuticals, Inc is −170% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Winston Pharmaceuticals, Inc (WPHM)?
The return on equity (ROE) of Winston Pharmaceuticals, Inc is −205% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Winston Pharmaceuticals, Inc (WPHM)?
On an EBIT basis the return on assets of Winston Pharmaceuticals, Inc is −104% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Winston Pharmaceuticals, Inc (WPHM)?
The operating margin of Winston Pharmaceuticals, Inc is −146% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Winston Pharmaceuticals, Inc (WPHM)?
Revenue at Winston Pharmaceuticals, Inc is growing −6.8% versus a year earlier (3y avg +67.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
Free · no account needed
Watch Winston Pharmaceuticals, Inc in the live analysis
One click puts Winston Pharmaceuticals, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Thin data
Sep 28, 2026